MISSISSAUGA, Ontario — A former Goldman Sachs executive will join Valeant Pharmaceuticals as EVP and CFO.
Howard Schiller will take over the position from Philip Loberg, who has been serving as Valeant's interim CFO on Dec. 1. Prior to his new role, Schiller was COO for Goldman Sachs' investment banking division until his retirement in January.
"The board of directors and I are delighted that Howard has agreed to join our company," Valeant chairman and CEO J. Michael Pearson said. "Howard brings an unquestioned intellect, tremendous relevant experience, an impressive track record of success, and a humble demeanor which will fit well with our company. I also want to thank Phil for the role he has performed these past twelve months and I am pleased that he will continue to play a key role in our financial organization."